MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21WAF1/CIP1

Background:Increasing evidence has shown that microRNAs (miRNAs) can serve as oncogenes and tumour suppressors to participate in tumour development. However, the roles of miRNAs in chemoresistance of human lung adenocarcinoma (LA) remain largely undefined.Methods:On the basis of miRNA microarray data, miR-224 was identified as the most upregulated miRNA in cisplatin (DDP; cis-diamminedichloroplatinum II)-resistant A549 cells compared with parental A549 cells. The aim of our study was to investigate the roles of miR-224 in the formation of DDP-resistant phenotype of LA cells and its possible molecular mechanisms.Results:Here we showed that miR-224 could promote the in vitro and in vivo DDP resistance of LA cells via regulating G1/S cell cycle transition and apoptosis. p21WAF1/CIP1, a potent cyclin-dependent kinase inhibitor, was identified as the direct and functional target gene of miR-224. Overexpression of p21WAF1/CIP1 could phenocopy the effect of miR-224 downregulation and silencing of p21WAF1/CIP1 could partially reverse the effect of miR-224 downregulation on DDP resistance of DDP-resistant LA cells. In addition, miR-224 could affect the G1/S transition of cell cycle and apoptosis in LA cells through the p21WAF1/CIP1-pRb pathway and the intrinsic mitochondrial death pathway. Furthermore, miR-224 was found to be downregulated in DDP-responding LA tissues, and its expression was inversely correlated with p21WAF1/CIP1. Multivariate analyses indicated that the status of miR-224 might be an independent prognostic factor for predicting the survival of LA patients.Conclusions:Our findings shed novel light on the roles of miR-224/p21WAF1/CIP1 signalling in the DDP resistance of LA cells, and targeting it will be a potential strategic approach for reversing the DDP resistance in human LAs.

[1]  E. Seim,et al.  Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. , 1989, Journal of clinical pathology.

[2]  Bing Feng,et al.  MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. , 2012, Cancer letters.

[3]  W. Zou Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[4]  Xi Chen,et al.  Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.

[5]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[6]  P. Kuppen,et al.  Natural killer cells: from "disturbing" background to central players of immune responses. , 2005, Molecular immunology.

[7]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Wiendl,et al.  Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? , 2007, Seminars in cancer biology.

[9]  R. Rosell,et al.  DNA repair and cisplatin resistance in non-small-cell lung cancer. , 2002, Lung cancer.

[10]  Jia Yu,et al.  MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. , 2013, Die Pharmazie.

[11]  B. Tait,et al.  HLA expression and cancer--14th IHIWS immunohistochemistry quality control exercise exchange results. , 2007, Tissue antigens.

[12]  Christophe Benoist,et al.  Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. , 2007, Immunity.

[13]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[14]  R. Rouzier,et al.  HLA‐G1 and HLA‐G5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment , 2012, European journal of immunology.

[15]  Eddie Reed,et al.  Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). , 2004, Oncology reports.

[16]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[17]  D. Mu,et al.  MicroRNAs and lung cancers: from pathogenesis to clinical implications , 2012, Frontiers of Medicine.

[18]  S. Lu,et al.  Upregulation of microRNA-224 confers a poor prognosis in glioma patients , 2013, Clinical and Translational Oncology.

[19]  R. Kobayashi,et al.  Pivotal Role of the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Apoptosis and Autophagy* , 2008, Journal of Biological Chemistry.

[20]  A. Chung,et al.  MicroRNA‐224 is up‐regulated in hepatocellular carcinoma through epigenetic mechanisms , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[22]  Yi Tie,et al.  miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. , 2012, Lung Cancer.

[23]  H. Friess,et al.  Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer , 2012, British Journal of Cancer.

[24]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[25]  L. Schiffmann,et al.  Is the lymph node ratio superior to the Union for International Cancer Control (UICC) TNM system in prognosis of colon cancer? , 2013, World Journal of Surgical Oncology.

[26]  K. Chayama,et al.  Involvement of microRNA‐224 in cell proliferation, migration, invasion, and anti‐apoptosis in hepatocellular carcinoma , 2013, Journal of gastroenterology and hepatology.

[27]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[28]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[29]  Federica Cavallo,et al.  2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.

[30]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. De,et al.  MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14) , 2011, Oncogene.

[32]  Hui Wang,et al.  Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer , 2013, Diagnostic Pathology.

[33]  Yanqing Ding,et al.  microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPP1 and PHLPP2 , 2013, Clinical Cancer Research.

[34]  Hein Putter,et al.  FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer , 2011, Cancer Microenvironment.

[35]  Hua-sheng Xiao,et al.  miRNAs modulate the drug response of tumor cells , 2009, Science in China Series C: Life Sciences.

[36]  H. Putter,et al.  The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer , 2010, Clinical Cancer Research.

[37]  Long-Bang Chen,et al.  MicroRNA‐200b reverses chemoresistance of docetaxel‐resistant human lung adenocarcinoma cells by targeting E2F3 , 2012, Cancer.

[38]  Kuo-Bin Li,et al.  Profiling MicroRNA Expression in Hepatocellular Carcinoma Reveals MicroRNA-224 Up-regulation and Apoptosis Inhibitor-5 as a MicroRNA-224-specific Target* , 2008, Journal of Biological Chemistry.

[39]  Wei De,et al.  Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) , 2011, Journal of experimental & clinical cancer research : CR.

[40]  C. Sen,et al.  miRNA in Wound Inflammation and Angiogenesis , 2012, Microcirculation.

[41]  A. Martayan,et al.  HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant , 2007, The American journal of surgical pathology.

[42]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[43]  J. Amiel,et al.  miRNA, development and disease. , 2012, Advances in genetics.

[44]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[45]  G. Hannon,et al.  Control of translation and mRNA degradation by miRNAs and siRNAs. , 2006, Genes & development.

[46]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[47]  Xianghuo He,et al.  Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region , 2010, Oncogene.

[48]  J. Yun,et al.  MiR-663, a microRNA targeting p21WAF1/CIP1, promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma , 2012, Oncogene.

[49]  Hein Putter,et al.  Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.

[50]  Hong Yang,et al.  Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer , 2007, Modern Pathology.

[51]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[52]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[53]  J. Galon,et al.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.

[54]  E. Thiel,et al.  Journal of Translational Medicine in Situ Analysis of Foxp3+ Regulatory T Cells in Human Colorectal Cancer , 2006 .

[55]  H. Putter,et al.  Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis , 2004, Laboratory Investigation.

[56]  G. Fleuren,et al.  HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression , 2007, BMC Cancer.

[57]  Yingjun Zhao,et al.  MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. , 2011, Carcinogenesis.

[58]  R. Tollenaar,et al.  Natural killer cells infiltrating colorectal cancer and MHC class I expression. , 2005, Molecular immunology.

[59]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[60]  Shuji Ogino,et al.  Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.

[61]  C. Yau,et al.  Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations , 2013, The American Journal of Gastroenterology.

[62]  G. Ferrara,et al.  HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. , 2005, Human immunology.

[63]  Ting He,et al.  p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell , 2010, BMC Cancer.

[64]  A. Warth,et al.  Tumor–microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma , 2013, Genes, chromosomes & cancer.

[65]  Zhimin Zhang,et al.  MicroRNA‐224 is upregulated in HepG2 cells and involved in cellular migration and invasion , 2010, Journal of gastroenterology and hepatology.

[66]  I. Ellis,et al.  Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.

[67]  Donald C. Chang,et al.  The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function , 2007, Molecular biotechnology.

[68]  D. Geraghty,et al.  Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.

[69]  B. Hantash,et al.  Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies. , 2012, Tissue antigens.

[70]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[71]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Liping Xie,et al.  Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. , 2008, Cancer letters.

[73]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[74]  S. Dahrouge,et al.  Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. , 2007, Cancer treatment reviews.

[75]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[76]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[77]  Huiyong Shen,et al.  MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. , 2012, Biochemical and biophysical research communications.

[78]  M. Holcik,et al.  Translation control in apoptosis. , 2012, Experimental oncology.

[79]  Shengdian Wang,et al.  Accumulation of Foxp3+ T Regulatory Cells in Draining Lymph Nodes Correlates with Disease Progression and Immune Suppression in Colorectal Cancer Patients , 2010, Clinical Cancer Research.

[80]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[81]  A. Martayan,et al.  HLA-E: Strong Association with β2-Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides1 , 2008, The Journal of Immunology.

[82]  G. Fogel,et al.  From pluripotency to islets: miRNAs as critical regulators of human cellular differentiation. , 2012, Advances in genetics.

[83]  I. Talbot,et al.  The inflammatory response within Dukes’ B colorectal cancers: implications for progression of micrometastases and patient survival , 2000, American Journal of Gastroenterology.

[84]  Hong Yang,et al.  Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[85]  Masao Tanaka,et al.  Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer , 2010, Cancer Immunology, Immunotherapy.

[86]  Jing Xian Lee,et al.  Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. , 2006, Biochemical and biophysical research communications.

[87]  Thomas Tuschl,et al.  MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.

[88]  Thomas Tuschl,et al.  miRNAs in human cancer , 2011, The Journal of pathology.

[89]  J Ma,et al.  MicroRNA and drug resistance , 2010, Cancer Gene Therapy.

[90]  G. Russ,et al.  The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. , 2004, Human immunology.

[91]  F. Ghiringhelli,et al.  Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.

[92]  De-Pei Liu,et al.  MicroRNAs: key participants in gene regulatory networks. , 2003, Current opinion in chemical biology.

[93]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[94]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[95]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[96]  M. Kloor,et al.  Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial , 2012, British Journal of Cancer.

[97]  R. Place,et al.  Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells , 2008, Molecular Cancer Therapeutics.

[98]  K. Koretz,et al.  Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. , 1991, Cancer research.

[99]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[100]  J. Bertino,et al.  Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. , 1997, Cancer research.

[101]  Hong Yang,et al.  Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. , 2007, American journal of clinical pathology.

[102]  N. Rouas-Freiss,et al.  Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. , 2003, Human immunology.

[103]  I. Cascorbi,et al.  miRNAs as mediators of drug resistance. , 2012, Epigenomics.

[104]  M. Joshi,et al.  Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.

[105]  Ping Yang,et al.  Lung cancer in China: challenges and interventions. , 2013, Chest.

[106]  Ying Huang,et al.  Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines , 2011, Acta Pharmacologica Sinica.

[107]  S. Fox,et al.  Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients , 2009, Clinical Cancer Research.

[108]  Hong Yang,et al.  Expression of Human Leukocyte Antigen G (HLA-G) Correlates with Poor Prognosis in Gastric Carcinoma , 2007, Annals of Surgical Oncology.